Correlation between the systemic clearance of drugs and their food effects in humans

Drug Development and Industrial Pharmacy

Volumn 37, Issue 11, 2011, Pages 1311-1317

  Marasanapalle, Venugopal P ^a   Boinpally, Ramesh R ^b   Zhu, Haijian ^a   Grill, Andreas ^a   Tang, Fuxing ^a  

^a Forest Research Institute   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Blood flow; Clearance; Food effect; Metabolism; Modeling; Permeability and solubility

Indexed keywords

CHLOROQUINE; DIAZEPAM; DIPRAFENONE; FLUCONAZOLE; METOPROLOL; PINDOLOL; PREDNISOLONE; PRIMAQUINE; PROPAFENONE; PROPRANOLOL; PYRAZINAMIDE; QUINIDINE; STAVUDINE; THEOPHYLLINE; TIMOLOL;

AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG PENETRATION; DRUG SOLUBILITY; FOOD DRUG INTERACTION; INTESTINE BLOOD FLOW;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BRAIN; CATTLE; CEFOTAXIME; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MENINGITIS, BACTERIAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 80053950960     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.571697     Document Type: Article

References (73)

1. Read NW, Sugden K. (1988). Gastrointestinal dynamics and pharmacology for the optimum design of controlled-release oral dosage forms. Crit Rev Ther Drug Carrier Syst, 4:221-263. (Pubitemid 18003661)
2. Vishwanathan S. (2005). The latest in POP (tablet) technology. In Pharmaceutical Formulation & Quality, Vol. 7, pp. 32-34.
3. Singh BN. (1999). Effects of food on clinical pharmacokinetics. Clin Pharmacokinet, 37:213-255. (Pubitemid 29452756)
4. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. (1999). Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet, 36:233-254. (Pubitemid 29178760)
5. CDER. (2002). Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies, FDA, Vol. 2004-2005.
6. Welling PG. (1984). Interactions affecting drug absorption. Clin Pharmacokinet, 9:404-434. (Pubitemid 14021621)
7. Marasanapalle VP, Crison JR, Ma J, Li X, Jasti BR. (2009). Investigation of some factors contributing to negative food effects. Biopharm Drug Dispos, 30:71-80.
8. Midha KK, McKay G, Rawson MJ, Korchinski ED, Hubbard JW. (2001). Effects of food on the pharmacokinetics of methylphenidate. Pharm Res, 18:1185-1189. (Pubitemid 32900405)
9. Drabant S, Nemes KB, Horváth V, Tolokán A, Grézal G, Anttila M et al. (2004). Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers. Eur J Pharm Biopharm, 58:689-695. (Pubitemid 39297118)
10. Hörter D, Dressman JB. (2001). Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev, 46:75-87.
11. Crauste-Manciet S, Decroix M, Farinotti R, Chaumeil J. (1997). Cefpodoxime-proxetil hydrolysis and food effects in the intestinal lumen before absorption: in vitro comparison of rabbit and human material. Int j Pharm, 157:153-161. (Pubitemid 27471167)
12. McLean AJ, McNamara PJ, duSouich P, Gibaldi M, Lalka D. (1978). Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism. Clin Pharmacol Ther, 24:5-10. (Pubitemid 8407204)
13. Daneshmend TK, Roberts CJ. (1982). The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: A study with labetalol. Br J Clin Pharmacol, 14:73-78. (Pubitemid 13147516)
14. Melander A. (1978). Influence of food on the bioavailability of drugs. Clin Pharmacokinet, 3:337-351. (Pubitemid 9013897)
15. Williams L, Hill DP Jr, Davis JA, Lowenthal DT. (1996). The influence of food on the absorption and metabolism of drugs: An update. Eur J Drug Metab Pharmacokinet, 21:201-211. (Pubitemid 27032506)
16. Melander A, Danielson K, Scherstén B, Wahlin E. (1977). Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther, 22:108-112. (Pubitemid 8155120)
17. Liedholm H, Melander A. (1986). Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation. Clin Pharmacol Ther, 40:29-36. (Pubitemid 16057978)
18. Axelson JE, Chan GL, Kirsten EB, Mason WD, Lanman RC, Kerr CR. (1987). Food increases the bioavailability of propafenone. Br J Clin Pharmacol, 23:735-741. (Pubitemid 17087976)
19. Wilkinson GR. (1997). The effects of diet, aging and diseasestates on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev, 27:129-159. (Pubitemid 27417870)
20. Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413-420.
21. Wu CY, Benet LZ. (2005). Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res, 22:11-23. (Pubitemid 40558141)
22. Wacher VJ, Salphati L, Benet LZ. (2001). Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev, 46:89-102.
23. Carlisle KM, Halliwell M, Read AE, Wells PN. (1992). Estimation of total hepatic blood flow by duplex ultrasound. Gut, 33:92-97.
24. Madsen JL, Søndergaard SB, Møller S. (2006). Meal-induced changes in splanchnic blood flow and oxygen uptake in middleaged healthy humans. Scand J Gastroenterol, 41:87-92. (Pubitemid 43030896)
25. Guyton AC, Hall JE. (1996). Textbook of Medical Physiology, Saunders Company, Philadelphia.
26. Svensson CK, Edwards DJ, Mauriello PM, Barde SH, Foster AC, Lanc RA et al. (1983). Effect of food on hepatic blood flow: Implications in the "food effect" phenomenon. Clin Pharmacol Ther, 34:316-323. (Pubitemid 13006299)
27. Lindenberg M, Kopp S, Dressman JB. (2004). Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm, 58:265-278. (Pubitemid 39037234)
28. Bolger BM. (2007). In silico prediction of fraction absorbed. In Therapeutic Applications of Computational Biology and Chemistry. TABAC simulations plus, Inc., Cambridge, UK.
29. Connolly SJ, Kates RE, Lebsack CS, Harrison DC, Winkle RA. (1983). Clinical pharmacology of propafenone. Circulation, 68:589-596. (Pubitemid 13050596)
30. Hollmann M, Brode E, Hotz D, Kaumeier S, Kehrhahn OH. (1983). Investigations on the pharmacokinetics of propafenone in man. Arzneimittelforschung, 33:763-770. (Pubitemid 13087997)
31. Koytchev R, Alken RG, Mayer O, Smith I, Greenwood M. (1996). Influence of food on the bioavailability and some pharmacokinetic parameters of diprafenone-a novel antiarrhythmic agent. Eur J Clin Pharmacol, 50:315-319.
32. NCSS. (2006). User's Guide: Regression and curve fitting. NCSS, Kaysville, Utah.
33. Roff D. (2002). Introduction to computer-intensive methods of data analysis in biology. Cambridge University Press, New York.
34. Mora R. (2009). Vol. 2009. Department of Economics, Universidad Carlos III De Madrid.
35. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. (1990). Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther, 253:387-394. (Pubitemid 20141526)
36. McKinnon RA, Burgess WM, Hall PM, Roberts-Thomson SJ, Gonzalez FJ, McManus ME. (1995). Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut, 36:259-267.
37. Peters WH, Kremers PG. (1989). Cytochromes P-450 in the intestinal mucosa of man. Biochem Pharmacol, 38:1535-1538. (Pubitemid 19123344)
38. Murray GI, Barnes TS, Sewell HF, Ewen SW, Melvin WT, Burke MD. (1988). The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. Br J Clin Pharmacol, 25:465-475.
39. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. (1987). Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest, 80:1029-1036. (Pubitemid 18075638)
40. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. (1992). Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest, 90:1871-1878.
41. Melander A, McLean A. (1983). Influence of food intake on presystemic clearance of drugs. Clin Pharmacokinet, 8:286-296. (Pubitemid 13069548)
42. Welling PG. (1996). Effects of food on drug absorption. Annu Rev Nutr, 16:383-415.
43. Ogiso T, Iwaki M, Tanino T, Kawafuchi R, Hata S. (1994). Effect of food on propranolol oral clearance and a possible mechanism of this food effect. Biol Pharm Bull, 17:112-116. (Pubitemid 24056995)
44. Mäntylä R, Männistö P, Nykänen S, Koponen A, Lamminsivu U. (1983). Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. Eur J Clin Pharmacol, 24:227-230. (Pubitemid 13147716)
45. Ochs HR, Knüchel M. (1984). Pharmacokinetics and absolute bioavailability of diltiazem in humans. Klin Wochenschr, 62:303-306. (Pubitemid 14167952)
46. Du Souich P, Lery N, Lery L, Varin F, Boucher S, Vezina M et al. (1990). Influence of food on the bioavailability of diltiazem and two of its metabolites following the administration of conventional tablets and slow-release capsules. Biopharm Drug Dispos, 11:137-147. (Pubitemid 20164632)
47. Levien TL, Baker DE. (2003). Cytochrome P450 drug interactions. In Pharmacist's Letter, pp. 1-4.
48. Gustafsson LL, Walker O, Alván G, Beermann B, Estevez F, Gleisner L et al. (1983). Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol, 15:471-479. (Pubitemid 13114651)
49. Tulpule A, Krishnaswamy K. (1982). Effect of food on bioavailability of chloroquine. Eur J Clin Pharmacol, 23:271-273. (Pubitemid 12028467)
50. Trenk D, Wagner F, Sachs W, Jähnchen E. (1989). Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man. Eur J Clin Pharmacol, 37:313-316. (Pubitemid 19242743)
51. Hardman JG, Limbird LE, Gilman AG. (Eds.) (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics, The McGraw- Hill Companies, Inc., New York, NY.
52. Sandow N. (2003). Vol. 2004 RxList LLC. Electronic Source: www. rxlist.com
53. Cuong BT, Binh VQ, Dai B, Duy DN, Lovell CM, Rieckmann KH et al. (2006). Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects?. Br J Clin Pharmacol, 61:682-689. (Pubitemid 43794794)
54. Drugs.com. (2010). Vol. 2010 Drugsite Trust.
55. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P et al. (2006). DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res, 34:D668-D672.
56. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D et al. (2008). DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res, 36:D901-D906. (Pubitemid 351149842)
57. Yamazaki A, Kumagai Y, Fujita T, Hasunuma T, Yokota S, Maeda M et al. (2007). Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam. J Clin Pharm Ther, 32:31-39. (Pubitemid 46213939)
58. Debruyne D, Ryckelynck JP. (1993). Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet, 24:10-27. (Pubitemid 23042127)
59. Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. (1994). Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol, 46:147-150. (Pubitemid 24101333)
60. Hsyu PH, Giacomini KM. (1985). Stereoselective renal clearance of pindolol in humans. J Clin Invest, 76:1720-1726. (Pubitemid 16196037)
61. Kiger JL, Lavene D, Guillaume MF, Guerret M, Longchampt J. (1976). The effect of food and clopamide on the absorption of pindolol in man. Int J Clin Pharmacol Biopharm, 13:228-232.
62. Bergrem H, Grøttum P, Rugstad HE. (1983). Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration. Eur J Clin Pharmacol, 24:415-419. (Pubitemid 13114914)
63. Tembo AV, Sakmar E, Hallmark MR, Weidler DJ, Wagner JG. (1976). Effect of food on the bioavailability of prednisone. J Clin Pharmacol, 16:620-624.
64. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, James GT, Nix DE. (1998). Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy, 18:1205-1211. (Pubitemid 28533871)
65. Zent C, Smith P. (1995). Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tuber Lung Dis, 76:109-113.
66. Ace LN, Jaffe JM, Kunka RL. (1983). Effect of food and an antacid on quinidine bioavailability. Biopharm Drug Dispos, 4:183-190. (Pubitemid 13107552)
67. Kaul S, Christofalo B, Raymond RH, Stewart MB, Macleod CM. (1998). Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection. Antimicrob Agents Chemother, 42:2295-2298. (Pubitemid 28420367)
68. Piscitelli SC, Kelly G, Walker RE, Kovacs J, Falloon J, Davey RT Jr et al. (1999). A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother, 43:647-650. (Pubitemid 29109533)
69. Jackson SH, Wiffen JK, Johnston A, Peverel-Cooper CA. (1985). The relationship between clearance of theophylline and age within the adult age range. Eur J Clin Pharmacol, 29:177-179. (Pubitemid 16246319)
70. Jonkman JH, van der Boon WJ, Balant LP, Le Cotonnec JY. (1985). Food reduces the rate but not the extent of the absorption of theophylline from an aqueous solution. Eur J Clin Pharmacol, 28:225-227.
71. Wilson TW, Firor WB, Johnson GE, Holmes GI, Tsianco MC, Huber PB et al. (1982). Timolol and propranolol: Bioavailability, plasma concentrations, and beta blockade. Clin Pharmacol Ther, 32:676-685. (Pubitemid 13093837)
72. Jaeger A, Flesch F, Kopferschmitt J, Sauder P. (1991). Vol. 2009. International Programme on Chemical Safety (IPCS) and the Canadian Centre for Occupational Health and Safety (CCOHS).
73. Volotinen M, Turpeinen M, Tolonen A, Uusitalo J, Mäenpää J, Pelkonen O. (2007). Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos, 35:1135-1141. (Pubitemid 46956434)